Curiox Biosystems sues BD and Waters for NDA breach
Curiox Biosystems — the developer of centrifuge-free (C-FREE) sample preparation technologies for automated flow cytometry workflows — has filed a lawsuit against Becton, Dickinson and Company (BD) and Waters Corporation for trade secret misappropriation, breach of contract and related claims in the United States District Court for the Northern District of California.
The lawsuit is based in part on the breach of a non-disclosure agreement (NDA) signed between Curiox and the BD Biosciences division, which was later acquired by Waters. The NDA prohibited BD Biociences from using Curiox’s confidential information to develop a competing product to Curiox’s C-FREE Pluto suite, including by reverse engineering and unauthorised replication.
As stated in the complaint, BD Biosciences seemingly expressed interest in a business relationship with Curiox in 2025. Subject to an NDA between the parties, Curiox entrusted a working Pluto workstation with a variety of prototype features under development to BD Biosciences in or around July 2025 for a limited business evaluation. Curiox also sent an application engineer and a Pluto workstation to BD’s California facility, with the engineer demonstrating the workstation to BD for approximately one week and providing confidential details regarding the design and operations of the product to BD engineers and scientists.
At BD’s request, Curiox allowed BD to retain the prototype for approximately another three weeks without Curiox’s engineer present. Following this evaluation period, Curiox continued to provide confidential information to BD in August and September 2025 regarding its Pluto technology, including prototypes of its Workflow Wizard software and documentation showing how Curiox developed automated scripts for the workstation based on simple user inputs.
Instead of moving forward with any commercial relationship with Curiox, BD and later Waters — which acquired the entire BD Biosciences division in February 2026 and has rebranded it as ‘Waters Biosciences’ — is alleged to have used Curiox’s proprietary and confidential technology to launch and accelerate development of its own so-called BD FACS360 Sample Preparation System. Neither BD nor Waters sought or obtained Curiox’s permission to use its proprietary and confidential Pluto technology in this way; as such, Curiox is seeking damages and injunctive relief to prevent further misuse of the technology the company invented and commercialised.
As the matter is now before the Court, Curiox does not intend to comment further at this time.
Australia signs Horizon Europe agreement in landmark deal
The agreement provides Australian researchers and organisations with access to Horizon Europe...
Suspicious citation numbers found in high-impact journals
The likely manipulation of citation numbers by research paper mills in high-impact cancer...
TGA developing reforms to strengthen sunscreen regulation
Brands would be required to test the SPF of their finished product, rather than just the base...
